DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit against AbbVie, Inc. Pharmaceutical Investing
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV Pharmaceutical Investing
DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel, Globally-Recognized Law Firm about Leading AbbVie Inc. Class Action Lawsuit Pharmaceutical Investing
ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - ABBV Pharmaceutical Investing
U.S. Food and Drug Administration Approves Two Opdivo® -Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Pharmaceutical Investing
Potent Ventures Completes Change of Business - Announces Name Change to "The Gummy Project Inc." and Change of Its Ticker Symbol to "GUMY" Biotech Investing
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, MYPS and ARQQ Pharmaceutical Investing
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib in Ulcerative Colitis Pharmaceutical Investing
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab in Crohn's Disease Pharmaceutical Investing
NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022 Market News
Data from Phase 2 PILOT Study of Bristol Myers Squibb's CAR T cell Therapy Breyanzi Show Substantial Durable Responses in Patients with Refractory or Relapsed Large B-cell Lymphoma After First-Line Therapy Pharmaceutical Investing
